Iain McInnes, PhD, FRCP

Professor of Medicine and Rheumatology
University of Glasgow
Glasgow, United Kingdom

Iain McInnes is a global leader in the field of arthritis research. He is Vice Principal and Head of College of Medical Veterinary and Life Sciences and Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology in the University of Glasgow. He has led numerous international clinical trials and pathogenesis investigation programmes in inflammatory arthritis. He is Director of the Versus Arthritis Centre of Excellence for Rheumatoid Arthritis. He is past chairman of the Foreum (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade and in 2019 became President of EULAR, the leading trans-national society for rheumatology across Europe. He has published >450 peer-reviewed original and review articles with an h-index of >100. He is a Fellow of the Royal Society of Edinburgh and Fellow of the Academy of Medical Sciences. He was made CBE in January 2019 by HM Queen Elizabeth II.

Disclosure information not submitted.

Presentation(s):

• 0304: Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 242: Raising the Bar: Implementing Treatment Goals in Clinical Practice for Inflammatory Joint Diseases

  Monday, November 14, 2022
  7:00 AM – 8:30 AM Eastern Time

• 2114: Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 2128: Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 2139: Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time